Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane phosphatase with tensin homology pseudogene 1 (TPTEP1) is classified as a long non-coding RNA transcript derived from the TPTE pseudogene family, lacking protein-coding capacity but exerting functional roles through its RNA sequence. TPTEP1 is notably downregulated in multiple cancers, including lung, glioma, ovarian, and gastric cancer, and acts as a tumor suppressor by inhibiting cell proliferation, cancer stemness, migration, invasion, and promoting apoptosis. Mechanistically, TPTEP1 functions as a competitive endogenous RNA (ceRNA), sponging oncogenic microRNAs (such as miR-328-5p, miR-106a-5p, miR-548d-3p), thereby upregulating tumor suppressor genes (e.g., SRCIN1, MAPK14, KLF9/PER1) and inactivating cancer-promoting pathways (PI3K/AKT, SRC, STAT3, MAPK). While not a traditional drug target (receptor, enzyme, transporter), TPTEP1's expression serves as a biomarker for prognosis and disease monitoring in several cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane phosphatase with tensin homology pseudogene 1 (TPTEP1).